Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174


Super-SILAC allows classification of diffuse large B-cell lymphoma subtypes by their protein expression profiles.

Deeb SJ, D'Souza RC, Cox J, Schmidt-Supprian M, Mann M.

Mol Cell Proteomics. 2012 May;11(5):77-89. doi: 10.1074/mcp.M111.015362. Epub 2012 Mar 21.


Machine Learning-based Classification of Diffuse Large B-cell Lymphoma Patients by Their Protein Expression Profiles.

Deeb SJ, Tyanova S, Hummel M, Schmidt-Supprian M, Cox J, Mann M.

Mol Cell Proteomics. 2015 Nov;14(11):2947-60. doi: 10.1074/mcp.M115.050245. Epub 2015 Aug 26.


A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.

Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, Braziel RM, Geng H, Iqbal J, Lenz G, Vose JM, Hans CP, Fu K, Smith LM, Li M, Liu Z, Gascoyne RD, Rosenwald A, Ott G, Rimsza LM, Campo E, Jaffe ES, Jaye DL, Staudt LM, Chan WC.

Clin Cancer Res. 2009 Sep 1;15(17):5494-502. doi: 10.1158/1078-0432.CCR-09-0113. Epub 2009 Aug 25.


System-wide perturbation analysis with nearly complete coverage of the yeast proteome by single-shot ultra HPLC runs on a bench top Orbitrap.

Nagaraj N, Kulak NA, Cox J, Neuhauser N, Mayr K, Hoerning O, Vorm O, Mann M.

Mol Cell Proteomics. 2012 Mar;11(3):M111.013722. doi: 10.1074/mcp.M111.013722. Epub 2011 Oct 20.


The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma.

Ruminy P, Etancelin P, Couronné L, Parmentier F, Rainville V, Mareschal S, Bohers E, Burgot C, Cornic M, Bertrand P, Lenormand B, Picquenot JM, Jardin F, Tilly H, Bastard C.

Leukemia. 2011 Apr;25(4):681-8. doi: 10.1038/leu.2010.302. Epub 2011 Jan 14.


Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.

Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM.

Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5. doi: 10.1073/pnas.0804295105. Epub 2008 Sep 2.


A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines.

Culpin RE, Proctor SJ, Angus B, Crosier S, Anderson JJ, Mainou-Fowler T.

Int J Oncol. 2010 Aug;37(2):367-76.


Systematic evaluation of label-free and super-SILAC quantification for proteome expression analysis.

Tebbe A, Klammer M, Sighart S, Schaab C, Daub H.

Rapid Commun Mass Spectrom. 2015 May 15;29(9):795-801. doi: 10.1002/rcm.7160.


BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.

Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, Connors JM, Staudt LM, Rimsza L, Jaffe E, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Gascoyne RD, Armitage JO, Weisenburger DD, Chan WC.

Clin Cancer Res. 2011 Dec 15;17(24):7785-95. doi: 10.1158/1078-0432.CCR-11-0267. Epub 2011 Sep 20.


Prognostic value of immunohistochemical classification of diffuse large B-cell lymphoma into germinal center B-cell and non-germinal center B-cell subtypes.

Saad AA, Awed NM, Abdel-Hafeez ZM, Kamal GM, Elsallaly HM, Alloub AI.

Saudi Med J. 2010 Feb;31(2):135-41.


Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas.

Lu X, Nechushtan H, Ding F, Rosado MF, Singal R, Alizadeh AA, Lossos IS.

Blood. 2005 Apr 1;105(7):2924-32. Epub 2004 Dec 9.


Stable isotope labeling by amino acids in cell culture (SILAC) and proteome quantitation of mouse embryonic stem cells to a depth of 5,111 proteins.

Graumann J, Hubner NC, Kim JB, Ko K, Moser M, Kumar C, Cox J, Schöler H, Mann M.

Mol Cell Proteomics. 2008 Apr;7(4):672-83. Epub 2007 Nov 28.


Mass spectrometric-based quantitative proteomics using SILAC.

Lanucara F, Eyers CE.

Methods Enzymol. 2011;500:133-50. doi: 10.1016/B978-0-12-385118-5.00008-6.


Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.

Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO, Chan WC, Vose JM.

J Clin Oncol. 2008 Oct 1;26(28):4587-94. doi: 10.1200/JCO.2007.15.9277. Epub 2008 Jul 28.


Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC.

Blood. 2004 Jan 1;103(1):275-82. Epub 2003 Sep 22.


Gene expression profiling of diffuse large B-cell lymphoma.

Rosenwald A, Staudt LM.

Leuk Lymphoma. 2003;44 Suppl 3:S41-7. Review.


A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.

Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM.

Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6. Epub 2003 Aug 4.


Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.

Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink HK, Staudt LM, Campo E, Rosenwald A; Lymphoma/Leukemia Molecular Profiling Project..

Blood. 2005 Nov 1;106(9):3183-90. Epub 2005 Jul 26.

Supplemental Content

Support Center